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Analytical exploration of potential 
pathways by which Diabetes 
Mellitus Impacts tuberculosis 
epidemiology
susanne F. Awad1,2, Soha R. Dargham1, Ryosuke omori1,3,4,5, Fiona pearson2, 
Julia A. Critchley2 & Laith J. Abu-Raddad  1,5,6
We aimed to develop a conceptual framework of diabetes mellitus (DM) effects on tuberculosis (TB) 
natural history and treatment outcomes, and to assess the impact of these effects on TB-transmission 
dynamics. The model was calibrated using TB data for India. A conceptual framework was developed 
based on a literature review, and then translated into a mathematical model to assess the impact 
of the DM-on-TB effects. The impact was analyzed using TB-disease incidence hazard ratio (HR) and 
population attributable fraction (PAF) measures. Evidence was identified for 10 plausible DM-on-TB 
effects. Assuming a flat change of 300% (meaning an effect size of 3.0) for each DM-on-TB effect, 
the HR ranged between 1.0 (Effect 9-Recovery) and 2.7 (Effect 2-Fast progression); most effects did 
not have an impact on the HR. Meanwhile, TB-disease incidence attributed directly and indirectly to 
each effect ranged between −4.6% (Effect 7-TB mortality) and 34.5% (Effect 2-Fast progression). The 
second largest impact was for Effect 6-Disease infectiousness at 29.9%. In conclusion, DM can affect TB-
transmission dynamics in multiple ways, most of which are poorly characterized and difficult to assess 
in epidemiologic studies. The indirect (e.g. onward transmission) impacts of some DM-on-TB effects are 
comparable in scale to the direct impacts. While the impact of several effects on the HR was limited, the 
impact on the PAF was substantial suggesting that DM could be impacting TB epidemiology to a larger 
extent than previously thought.
Tuberculosis (TB) disease burden remains high in parts of the world1,2. A quarter of the world’s population has 
been infected with M. tuberculosis, of whom a fraction will develop active disease within their lifetime1,2. In 2017, 
10.0 million incident cases were estimated with TB disease and 1.3 million died from it1,2. There is a recognition 
that major reduction in TB burden is difficult to achieve without controlling its risk factors. The World Health 
Organization’s (WHO) post-2015 TB strategy calls for prioritization of interventions addressing the key TB risk 
factors including diabetes mellitus (DM)3.
A synergetic relationship between TB and DM has been suspected for decades4, but has only recently emerged 
as a global-health concern, with the growing DM prevalence in TB endemic regions5,6, Globally, an estimated 425 
million people live with DM; a number that is expected to grow to 629 million by 20457. Low- and middle-income 
countries are the epicenter of the increasing DM burden accounting for over 80% of global DM cases7.
DM appears to increase the risk of TB disease by about three-fold5,6,8, and to have profound adverse impact 
on TB-treatment outcomes (e.g. DM appears to increase the risk of TB death by two to four-fold, and TB dis-
ease relapse and recurrence by two-fold, among others)6,9–13. DM is suspected to account for a considerable pro-
portion of TB-disease incident cases14–21, highlighting the importance of the joint TB-DM epidemic. Yet, our 
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understanding of the underlying biological/epidemiological interactions between TB and DM remains limited. 
It is critical to delineate these complex interactions to assess both the direct and indirect implications of DM on 
TB’s burden6,22.
Most indirect implications of TB-DM interactions relate to onward transmission of TB infection. DM may 
increase the risk of development of TB disease, which is a direct (etiological) effect for DM on TB. However, 
with the ensuing pool of infectious individuals with TB disease, TB transmission would increase leading to more 
individuals with TB infection. The latter onward-transmission effect is an indirect effect of DM increasing the 
risk of development of TB disease. While conventional population attributable fraction (PAF) approaches (such 
as Levin’s formula23) can estimate the direct population impact of DM on TB disease, they do not account for 
the indirect impacts. The latter, however, can be captured and estimated through mathematical modeling of 
TB-transmission dynamics in the population.
Against this background, we aimed first to develop a conceptual framework that describes the different pos-
sible pathways by which DM could affect TB natural history and treatment outcomes. Second, we translated 
this conceptual framework into a population-based mathematical TB-DM model incorporating these effects and 
their direct and indirect impacts. Third, we assessed the impacts of these effects (using a “flat change” of 300% to 
standardize the effect size) on TB epidemiology by applying the model in a representative high TB-burden setting. 
The study thus provides a theoretical analytical investigation of the implications of the DM effects (alone and in 
combinations) on TB epidemiology for an improved understanding of the TB-DM synergy. Using a standardized 
effect size also enabled the investigation and comparison of the theoretical importance of both direct and indirect 
impacts for each potential pathway. The research questions along with the corresponding methods are summa-
rized in Figure 1. This study approach was deemed necessary as we do not yet have sufficient empirical evidence 
to quantify the precise and exact effect sizes of most of these DM-on-TB effects. Therefore, our work presents an 
original and comprehensive theoretical assessment of the potential TB-DM interactions and their implications on 
TB epidemiology, particularly how important indirect (or true population) effects might be for each pathway. It 
does not aim to provide precise information on the absolute actual impact of each pathway on TB epidemiology.
Methods
Conceptual framework for TB-DM interactions. We conducted a literature review based on which we 
developed a conceptual framework of TB-DM interactions. Available publications on the TB-DM interactions 
were reviewed through searches using the PubMed and Google Scholar databases up to May 2017. For inclu-
siveness, we used broad search criteria with terms exploded to cover all subheadings. Any publication reporting 
on TB-DM interactions qualified for inclusion in this review. No language or year restrictions were imposed. 
The review identified the plausible mechanisms and effects by which DM can influence TB’s natural history and 
treatment outcomes.
Mathematical model, data sources, and model fitting. We constructed a population-based dynam-
ical TB-DM mathematical model to represent the developed conceptual framework and assess the direct and 
indirect impacts of the effects of DM on TB. The model is an adaptation of an earlier TB-transmission model24 
that was extended to include DM and the postulated TB-DM interactions. The model consisted of a system of 
coupled nonlinear differential equations stratifying the population according to TB infection status and stage, 
disease form, treatment status, and recovery status.
The model incorporated two TB natural histories depending on DM status (Fig. 2). DM was parsimoniously 
included in the model by stratifying a specific and fixed proportion of the population to be living with DM. 
DM-free individuals were also assumed to be susceptible but at risk of TB infection. Newly infected individuals 
progress into either latent-slow TB infection (LSI) or latent-fast TB infection (LFI). Individuals with LSI develop 
TB disease at a rate corresponding to a 5% lifetime risk of developing TB disease24–27—meaning that the risk of 
developing TB disease is so small that only 5% of individuals in LSI will eventually develop the disease, simply 
Figure 1. List of the key research questions assessed in this study along with the methods used to address them.
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because they would have reached the end of their life expectancy before developing TB disease. Individuals with 
LFI develop TB disease within a short duration after infection24–26.
TB disease was stratified into three clinically-relevant forms: smear-positive pulmonary (SP-PTB), 
smear-negative pulmonary (SN-PTB), and extra-pulmonary (EP-TB)24,27. Pulmonary TB disease forms were 
assumed infectious, but at varying levels24,28.
Treated individuals without DM proceed to the recovery state in six months reflecting the typical 6-months 
treatment course under the directly-observed treatment, short course (DOTS)29. Treated and recovered individ-
uals can be re-exposed to a new TB infection, and subsequently proceed to TB disease.
DM individuals followed a similar TB natural history to that of non-DM individuals, but the natural history 
was modulated by specific effects of having DM. DM was assumed to affect TB’s natural history and treatment 
outcomes at the different TB stages. Further details on the model can be found in Supplementary Text S1.
Model parameters were chosen according to empirical evidence and through model fitting to data. 
Supplementary Table S1 lists the parameter values and their sources. Data for India were used to parameterize 
the country-specific parameters30,31. India was chosen as an illustrative example since both TB incidence and DM 
prevalence are high in this country32. Note that given that we used arbitrary effect sizes for the interaction effects, 
this exploratory analysis does not provide estimates of the population impact of DM on TB in India.
The model was fitted to TB-incidence (i.e. 217 per 100,000 population per year), mortality (i.e. 39 per 100,000 
population per year), and case fatality (i.e. 0.17) rates for the year 2015, as obtained from the WHO’s Global 
Figure 2. A conceptual framework for the TB-DM epidemiologic synergy. The black lines indicate the 
transitions within TB’s natural history and treatment states. The red lines indicate the 10 plausible effects of DM 
on TB natural history and treatment outcomes.
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Health Observatory data repository30; and to national DM prevalence (i.e. 8.6%) for the year 2015, as obtained 
from the International Diabetes Federation31. Three country-specific parameters were derived by model fitting to 
data: respiratory contact rate, TB case detection rate, and DM-related mortality rate.
The population size was held constant to disentangle the TB-DM epidemiological effects from the demo-
graphic effects. All analyses were conducted assuming endemic equilibrium for TB. The model was coded and 
analyzed in MATLAB R2015a33.
Epidemiologic implications of TB-DM interactions. Using the model, we assessed the implications of 
each of the plausible/potential DM effects on TB epidemiology, individually and in combinations. For a stand-
ardized comparison of the impact across the different mechanisms, we assumed a flat change of 300% for each 
pathway by which DM affects TB; that is, a standard effect size (ES) of 3.0 for each mechanism with an expected 
ES ≥1, and (an inverse) ES of 1/3 for each mechanism with an ES <1. This specific choice of ES value is relevant 
but otherwise arbitrary, as we aimed to assess the impact given a specific standardized ES for all DM-on-TB 
effects. This value of ES of 3.0 was deemed reasonable given the strength of the observed association (for different 
but closely-related statistical measures) between TB and DM in systematic reviews and meta-analyses5,6,8. Noting 
that, for most effects, the ES as estimated in the literature was heterogeneous in value, had only suggestive evi-
dence with no assessed value, or could not be disentangled from the ES of another effect. While we used an ES of 
3.0 for each effect, our model is general and can assess theoretically the impact of any combination of ESs.
We assessed the TB-DM epidemiologic synergy using two population-level measures: incidence hazard 
ratio (HR) and “true” population attributable fraction (PAFTrue). The HR was defined as the ratio of TB disease 
incidence rates among those with DM over those with no DM, within the same population (Equation 2.1 of 
Supplementary Text S1).
The PAFTrue was assessed for three TB-disease outcome measures: incidence, prevalence, and mortality. 
For each, it was defined as the proportional reduction in the measure in a comparison between the measure 
in a scenario where there is TB-DM epidemiologic synergy (some active effects for DM on TB), compared to 
a counter-factual scenario where there is no TB-DM epidemiologic synergy (no active effect; Equation 2.2 of 
Supplementary Text S1). These two scenarios were simulated using the model by assuming an ES of 3.0 (or 1/3) 
in the epidemiologic-synergy scenario, and an ES of 1.0 in the no-epidemiologic-synergy scenario. This approach 
for assessing the PAF is labeled as “true” PAF34,35, because it captures the direct (etiological) effects of DM on TB, 
as well as the indirect (such as onward transmission) effects of DM on TB.
In addition to PAFTrue, we estimated the PAF using the conventional but simplistic Levin’s formula (PAFLevin)23, 
which cannot capture the indirect effects, for comparison purposes (Equation 2.3 of Supplementary Text S1). 
Strictly speaking, we assessed the PAFLevin for only the specific situation that it applies: assuming that DM 
increases the risk of developing TB disease by a factor of 3 (relative risk (RR) = 3), based on existing estimates5,6,8 
and not on a specific DM-on-TB effect.
Results
Conceptual framework for TB-DM interactions. Figure 2 illustrates the conceptual framework of 
TB-DM interactions that was developed based on the evidence gleaned from the literature review, for epide-
miologically-relevant effects with either robust or suggestive evidence. DM was accordingly postulated to affect 
TB’s natural history and treatment outcomes in 10 different potential ways. Each of these was labeled as “effect” 
and numbered accordingly. A description of each effect and citations to its supporting evidence can be found in 
Table 1. Of notice that the strength of the evidence based varied for each effect, and quite often was either poten-
tially biased, or estimated with wide confidence intervals.
There was evidence suggesting that DM may increase susceptibility to TB infection (Effect 1-Susceptibility)36–41—
an effect to be distinguished from that of increasing susceptibility to TB disease.
Ample evidence supported an increased risk of developing TB disease for those with DM5,8,10,42–50. However, 
this evidence did not differentiate the precise biological mechanism of whether DM is associated with increased 
proportion of TB infections entering the LFI state, as opposed to the LSI state (Effect 2-Fast progression); increased 
susceptibility to develop TB disease among those with LSI (Effect 3-Reactivation); and/or increased susceptibility 
to TB reinfection among those with LSI (Effect 4-Primary reinfection).
Several studies indicated that DM increases the proportion of developing SP-PTB disease (as opposed to 
SN-PTB) among those who progress to pulmonary TB disease (Effect 5-Smear positivity)51–60. DM was also found 
to be a risk factor for increased M. tuberculosis bacterial load51,54,61,62; a proxy biomarker for increased TB infec-
tiousness among those with pulmonary TB disease (Effect 6-Disease infectiousness)—that is, DM increasing the 
risk of TB transmission per one respiratory contact as a consequence of the higher bacterial load.
Strong evidence indicated that DM increases the risk of TB-related mortality among treated TB-disease indi-
viduals (Effect 7-TB mortality)12,13,52,53,60,61,63. We assumed, given biological plausibility, that the same effect applies 
for untreated TB disease individuals (Effect 7-TB mortality).
Several studies indicated that DM reduces the proportion of successful treatment among those undergoing 
TB treatment (through increased risk of treatment failure and multi-drug resistant TB; Effect 8-Treatment fail-
ure)12,13,57,64. Also, recent studies demonstrated a greater risk of persisting TB smear or sputum culture positivity 
by the second to third month of treatment, delaying the resolution of TB disease among those with DM compared 
to those without DM (Effect 9-Recovery)51,54,55,64–67.
Evidence indicated an increased susceptibility to TB reinfection after TB treatment and recovery among those 
with DM (Effect 10-Cured reinfection)12,13,64. Cured reinfection is defined as a subsequent episode of TB disease in 
a TB patient who received at least six months of TB treatment, but developed active TB after successful treatment 
(i.e. smear or sputum culture was negative at the end of the treatment period). Given biological plausibility, we 
assumed that the same effect applies to naturally recovered individuals.
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All these effects were incorporated in the conceptual framework, and in the TB-DM mathematical model, as 
delineated in Equation 2.2 of Supplementary Text S1.
Impact of TB-DM interactions on the hazard ratio of TB disease. Figure  3A shows the 
model-estimated HRs for the 10 TB-DM effects. The standardized ES of 3.0 (or 1/3) for each effect impacted the 
HR differently. Effect 2-Fast progression had the largest impact with an HR of 2.7, which is within the range found 
in observational studies8. Effect 3-Reactivation, Effect 1-Susceptibility, and Effect 4-Latent reinfection had an inter-
mediate HR impact in the range of 1.3–1.4, which is also within the range found in observational studies8. Effect 
10-Cured reinfection had a minor HR impact of 1.1, which is outside the range found in observational studies8. 
For the remaining effects (Effect 5-Smear positivity, Effect 6-Disease infectiousness, Effect 7-TB mortality, Effect 
8-Treatment failure, and Effect 9-Recovery), the HR was 1.0—these effects had no impact on the HR, which is also 
outside the range found in observational studies8.
By assessing all possible effect combinations (for those with HR >1.0), the HR ranged between 1.4 (Effect 
3-Reactivation and Effect 10-Cured reinfection) and 7.8 (combining all effects; Fig. 3B). Every combination that 
included Effect 2-Fast progression reached an HR of 3.0 or higher, but none of the combinations that did not 
include Effect 2-Fast progression reached an HR of 3.0 or higher.
By assessing all possible pairwise combinations for all effects, the HR ranged between 1.0 (for several pairwise 
combinations) and 3.8 (Effect 2-Fast progression and Effect 4-Latent reinfection; Supplementary Fig. S1A). Few of 
the pairwise combinations that included Effect 2-Fast progression reached an HR of 3.0 or higher, but none of the 
combinations that did not include Effect 2-Fast progression reached an HR of 3.0 or higher.
Variation in the effect size of each of the DM-on-TB effects and observed HR. In an additional 
one-way sensitivity analysis, the ES of each of the DM-on-TB effects was varied to yield the observed HR of 3.0 
(Fig. 4). For Effect 1-Susceptibility, Effect 5-Smear positivity, Effect 6-Disease infectiousness, Effect 7-TB mortality, 
Effect 8-Treatment failure, Effect 9-Recovery, and Effect 10-Cured reinfection, no value for the ES would yield an 
HR value of 3.0. However, for Effect 2-Fast progression, Effect 3-Reactivation, and Effect 4-Latent reinfection a value 
of 3.4, 24.0, and 12.0, respectively, would yield an HR value of 3.0. Moreover, the ranking of the impact on HR of 
the DM-on-TB effects barely changed regardless of the ES, appart from a minor change in the ranking of Effect 
1-Susceptibility, mainly due to the saturation of the impact of this effect on the HR (Fig. 4). The sensitivity of the 
model output to changes in TB fast progression has been also observed in a previous modelling study68.
The epidemiological impact of varying simultaneously the ES (from 1.5 to 5.0) of all pairwise combinations 
of the effects that individually had an HR >1.0 (for an ES of 3.0) was assessed in an additional sensitivity anal-
ysis (Fig. S3). For ES less than 4.0, the ranking of the impact on HR for the DM-on-TB effects was unchanged. 
However, for higher ES, there was one main change in the ranking; the scale of the HR for the combination of 
Effect 2-Fast progression and Effect 10-Cured reinfection became higher than other combinations, highlighting the 
importance of their synergy, possibly related to surpassing the reinfection threshold69–72.
Impact of TB-DM interactions on the population attributable fractions. Figure 5A shows the pro-
portion of TB-disease incidence attributed directly or indirectly (i.e. PAFTrue) to DM for the 10 TB-DM effects 
Effect Description
Statistical measure of 
effect as incorporated 
in the model
Expected range 
based on available 
evidence Sources
Effects of DM on TB’s natural history (TB infection and/or TB disease)
Effect 1-Susceptibility DM increases the susceptibility to TB infection Hazard ratio ≥1 36–40
Effect 2-Fast progression DM increases the proportion of TB infections entering latent-fast state as opposed to latent-slow state Proportion ratio ≥1
5,8,10,42–48
Effect 3-Reactivation DM increases the rate of developing TB disease among those with latent TB infection Rate ratio ≥1
5,8,10,42–48
Effect 4-Latent reinfection DM increases the susceptibility to TB reinfection among those with latent-slow TB infection Hazard ratio ≥1
5,8,10,42–48
Effect 5-Smear positivity DM increases the proportion of new PTB
# disease cases progressing to SP-
PTB* as opposed to SN-PTB$ Proportion ratio ≥1
51–60
Effect 6-Disease infectiousness DM increases the infectiousness of PTB (SP-PTB and SN-PTB) for both untreated and treated TB disease cases Factor ratio ≥1
51,54,61,62
Effect 7-TB mortality DM increases the hazard of TB-related mortality for both untreated and treated TB disease cases Hazard ratio ≥1
12,52,53,60,61,63
Effects of DM on TB treatment outcomes
Effect 8-Treatment failure DM reduces the proportion of successful treatment (through increased risk of treatment failure and MDR-TB¥) Proportion ratio ≥1
12,57,64
Effect 9-Recovery DM reduces the rate of TB recovery (i.e. prolongs the recovery time) for those who recover naturally or due to treatment Rate ratio ≥1
51,54,55,64–67
Effect 10-Cured reinfection DM increases the susceptibility to TB reinfection among those treated or recovered from TB disease Hazard ratio ≥1
12,64
Table 1. The plausible effects of diabetes mellitus (DM) on tuberculosis (TB) natural history and treatment 
outcomes. #PTB: Pulmonary TB; *SP-PTB: smear-positive pulmonary TB; $SN-PTB: smear-negative pulmonary 
TB; ¥MDR-TB: multi-drug resistant TB.
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assuming a standardized ES of 3.0 (or 1/3). PAFTrue for TB-disease incidence ranged between −4.6% (Effect 7-TB 
mortality) and 34.5% (Effect 2-Fast progression). The second largest PAFTrue at 29.9% was for Effect 6-Disease 
infectiousness (DM increasing TB infectiousness by three-fold). The lowest positive PAFTrue at 1.3% was for Effect 
5-Smear positivity.
Of notice, the impact of Effect 5-Smear positivity and Effect 6-Disease infectiousness on TB transmission 
dynamics were different, despite the apparent similarity in mechanism of action. Effect 6-Disease infectiousness 
increased TB transmission in the population by increasing the risk of TB transmission for a given infectious con-
tact. While Effect 5-Smear positivity also led to increased TB transmission in the population by increasing the pool 
of smear-positive TB cases, this effect was undermined by the fact that smear-positive TB cases had a higher risk 
of TB mortality (Supplementary Table S1).
The effect of DM on TB mortality (Effect 7-TB mortality) caused a negative PAFTrue of −4.6%, as the higher 
mortality of individuals with TB-DM reduced TB transmission in the population, and thus TB disease incidence 
(i.e. TB-DM individuals died before spreading the infection further).
Figure 3. Epidemiological impact of the 10 plausible effects of diabetes mellitus (DM) on tuberculosis (TB) 
natural history and treatment outcomes, as measured by the incidence hazard ratio (HR) of TB disease among 
those with DM compared to those without DM. (A) Results of the impact of each of the effects individually. (B) 
Results of the impact of all possible combinations of the effects that individually had an HR >1.0. Each DM on 
TB effect had a standardized effect size (ES) of 3.0 if the expected ES (based on evidence) is ≥1, and (an inverse) 
ES of 1/3 if the expected ES is <1 (red line).
Figure 4. Assessment of varying the effect size of each of the diabetes mellitus (DM) on tuberculosis (TB) 
effects to yield the observed hazard ratio (HR) of 3.0. HR is defined as the ratio of TB disease incidence rate 
among those with DM compared to those without DM.
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The predicted impact of DM on TB-disease incidence using Levin’s formula (assuming that DM increases the 
risk of developing TB disease by three-fold) was estimated at 14.7% (Fig. 5A). The latter should be seen as a base-
line for comparison of the different impacts.
Figure 5B shows the proportion of TB-disease prevalence attributed to DM for the 10 effects, assuming 
similary ES of 3.0 (or 1/3). The impact of each effect on TB-disease prevalence was overall similar to that on 
TB-disease incidence (Fig. 5B). The proportion of TB-disease prevalence attributed to each effect ranged between 
−7.1% (Effect 7-TB mortality) and 34.5% (Effect 2-Fast progression).
Figure 5C shows the proportion of TB-disease mortality attributed to DM for the 10 effects, assuming similary 
ES of 3.0 (or 1/3). The pattern was overall similar to that for TB-disease incidence and prevalence. The proportion 
of TB-disease mortality attributed to each effect ranged between 0.9% (Effect 5-Smear positivity) and 34.5% (Effect 
2-Fast progression). The effect on TB mortality (Effect 7-TB mortality) caused here a positive impact of 5.4%, versus 
the negative impacts on TB-disease incidence (−4.6%) and prevalence (−7.1%).
Supplementary Figure S1 shows the results for PAFTrue for all possible combinations of the five effects that indi-
vidually had the largest PAFTrue. The proportion of TB-disease incidence attributed to DM ranged between 22.5% 
(Effect 1-Susceptibility and Effect 4-Latent reinfection) and 89.1% (combining all effects). By assessing all possible 
Figure 5. Proportion of tuberculosis (TB) disease incidence (A), prevalence (B), and mortality (C) attributed 
to each of the effects of diabetes mellitus (DM) on TB natural history and treatment outcomes. These population 
attributable fraction (PAFTrue) measures were estimated as the proportional reduction in the measure in a 
comparison between the measure in a scenario where there is TB-DM epidemiologic synergy (that is some 
effect for DM on TB is active), compared to a counter-factual scenario where there is no TB-DM epidemiologic 
synergy. Each DM on TB effect had a standardized effect size (ES) of 3.0 if the expected ES (based on evidence) 
is ≥1, and (an inverse) ES of 1/3 if the expected ES is <1. The red bar (and line) in panel A is the estimated 
Levin’s formula population attributable fraction, assuming a relative risk (RR) of 3.0 for TB-disease incidence 
among DM versus non-DM individuals.
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pairwise combinations for all effects, the PAFTrue for incidence ranged between −3.5% (Effect 7-TB mortality and 
Effect 10-Cured reinfection) and 70.9% (Effect 2-Fast progression and Effect 6-Disease infectiousness; Supplementary 
Fig. S2B).
Table 2 shows a comparison of the impact of DM on TB-disease incidence as measured by PAFTrue and HR. 
Effect 2-Fast progression had the highest impact using both measures. There were some effects that had large 
impact on PAFTrue, but limited or no impact on HR, most notably Effect 6-Disease infectiousness that had the 
second largest PAFTrue.
Discussion
We investigated the mechanisms by which DM can affect TB natural history and treatment outcomes, and there-
fore can impact TB-transmission dynamics. Seven epidemiologically-relevant plausible effects for DM on TB 
natural history, and three for DM on TB treatment outcomes, were identified based on literature review. Informed 
by this empirical evidence, we developed a conceptual framework of DM’s effects on TB (Fig. 2), and trans-
lated it into a mathematical model to investigate the impact of these effects on TB-transmission dynamics. Our 
main findings show that conventional estimates of the PAF (that is using Levin’s formula) indicate that 15% of 
TB-disease incidence is attributable to DM (in India where the model was applied for Effect 2-Fast progression; 
Fig. 5A), but taking into account indirect effects (onward transmission), the “true” PAF could be two-fold higher 
at 35%. The “true” PAF, however, depends on which DM-on-TB effect (or combination of effects) is assumed to be 
active; looking at each listed pathway individually and assuming a standardized ES of 3.0 (or 1/3) yielded a “true” 
PAF that ranged from −5% to 35% (Fig. 5).
Although the 10 effects impacted TB-transmission dynamics (Fig. 5), the impact (for several of them) could 
not be captured by the HR (Fig. 3A)—the conventional epidemiologic measure of the TB-DM association. The 
reason is that the HR captures only the effects of DM on directly developing TB disease, but cannot capture effects 
that leads indirectly to more TB disease in the population. For example, evidence suggests a higher TB infec-
tiousness with DM (Effect 6-Disease infectiousness), because of higher M. tuberculosis bacterial load51,54,61,62. The 
higher infectiousness contributes to more TB transmission in the population, but this effect cannot be captured 
by a study that compares TB incidence among those with DM to those without DM (conventional cohort or 
case-control studies)—the higher infectiousness affects both comparison groups simultaneously.
Of the 10 investigated effects, only four resulted in an impact that could be actually measured by the HR 
(Fig. 3A). Even though the ES of each effect was standardized at 3.0, all effects had an HR <3; the HR was not 
a representative measure of the true ES of each effect. Effect 2-Fast progression resulted in the largest HR at 2.7, 
while Effect 3-Reactivation, Effect 1-Susceptibility, and Effect 4-Latent reinfection had HRs of only about 1.4. Also, 
based on the comparison between the measured HR assuming the standard ES of 3.0 and the actual pooled 
evidence for the TB-DM assosciation, including prospective (3.59, 95% confidence interval [CI] 2.25–5.73), ret-
rospective (1.55, 95% CI 1.39–1.72), and case-control studies (2.09, 95% CI 1.71–2.55); it seems that only Effect 
1-Susceptibility, Effect 2-Fast progression, Effect 3-Reactivation, and Effect 4-Latent reinfection can explain the 
TB-DM assosiation.
It is possible that the 10 TB-DM effects could be acting simultanously, and therefore their individual impacts 
on the HR are difficult (if not impossible) to disentangle. Figure 4 highlights that some pathways are impossi-
ble to result in an HR of 3.0 by themselves (i.e. Effect 1-Susceptibility, Effect 5-Smear positivity, Effect 6-Disease 
infectiousness, Effect 7-TB mortality, Effect 8-Treatment failure, Effect 9-Recovery, and Effect 10-Cured reinfection), 
while other pathways can reach an HR of 3.0 by themselves but only at very high effect sizes (i.e. effect size of 24 
and 12 for Effect 3-Reactivation and Effect 4-Latent reinfection, respectively).
Effect# PAFTrue HR
Effect 2-Fast progression 34.5% 2.7
Effect 6-Disease infectiousness 29.9% 1.0
Effect 8-Treatment failure 14.8% 1.0
Effect 4-Latent reinfection 11.1% 1.4
Effect 1-Susceptibility 9.9% 1.4
Effect 3-Reactivation 8.2% 1.3
Effect 9-Recovery 3.8% 1.0
Effect 10-Cured reinfection 1.7% 1.1
Effect 5-Smear positivity 1.3% 1.0
Effect 7-TB mortality −4.6% 1.0
If no effect of DM on TB 0.0% 1.0
Relevant reference measure 14.7%$ 3.0€
Table 2. The epidemiologic implications* of each of the plausible diabetes mellitus (DM) effects on tuberculosis 
(TB) natural history and treatment outcomes as measured by the “true” population attributable fraction 
(PAFTrue) and incidence hazard ratio (HR). #Effects are ordered from largest to lowest PAF. $PAF estimated using 
Levin’s formula23. €Typical effect size using different, but closely-related statistical measures (such as hazard ratio, 
relative risk, rate ratio, and odds ratio) of the strength of the observed TB-DM association5,6,8. *We assumed a 
standard effect size of 3.0 for each mechanism with an expected effect size ≥1 and (an inverse) effect size of 1/3 
for each mechanism with an effect size ≤1.
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The measured HR in an epidemiological study may reflect thus the combined effect of several individual 
effects (Fig. 3B and Supplementary Fig. S2A). For instance, by combining Effect 2-Fast progression and Effect 
3-Reactivation, the HR of 3.0 (suggested by the recently updated systematic review7) can be easily reached (Fig. 3B 
and Supplementary Fig. 4). Indeed, some combinations that included Effect 2-Fast progression reached an HR 
of 3.0 or higher, but none of the combinations that did not include Effect 2-Fast progression reached an HR of 
3.0 or higher. Even for some of the effects that alone did not have an HR >1 (e.g. Effect 6-Disease infectiousness, 
Effect 7-TB mortality, and Effect 8-Treatment failure), by combining them with Effect 2-Fast progression an HR 
higher than the HR of Effect 2-Fast progression alone was reached, higlighting synergy in combining these effects 
(Supplementary Fig. S2A). Supplementary Figure S3 also highlights the potential synergy in combining effects, 
and shows that the impact (i.e. ranking/importance) of some of the pairwise combinations of the TB-on-DM 
effects on HR may change at large values for the ES (here larger than 4.0).
These findings highlight how the focus on measures such as HR, relative risk, rate ratio, and odds ratio, to 
assess the TB-DM association, can be misleading. These measures cannot capture the actual impact of some 
TB-DM effects which influence TB epidemiology indirectly—the focus on such measures may be preventing us 
from appreciating the extent to which DM is influencing TB-transmission dynamics.
We found that the impact of DM on TB is better assessed using the “true” PAF (PAFTrue) as it captures both 
the direct and indirect impacts, and for all 10 effects. Taking Effect 6-Disease infectiousness (that had an HR = 1.0; 
Fig. 3A) as an example, 30% of TB-disease incidence was attributed to this effect (assuming three-fold increased 
TB infectiousness with DM; Fig. 5A). This large impact arises not only from the direct enhanced TB transmission 
from those with concurrent DM, but also from the indirect onward transmission with the larger pool of infected 
persons in the population.
Of all effects, assuming a standard ES, Effect 2-Fast progression had the largest impact (Fig. 5). This effect 
increases TB-disease incidence by increasing the fraction of infections that progress rapidly to TB disease (direct 
impact), but also increases (indirect impact) the onward transmission and circulation of TB among both DM and 
non-DM persons. It is striking that the indirect impact was comparable in scale to the direct impact. This can be 
seen by comparing the PAFTrue of 35% to that of PAFLevin of only 15% (the latter measures only the direct impact 
on incidence). These findings further demonstrate how the conventional approach to assess the PAF due to DM 
using PAFLevin14,17–21, could be underestimating the extent to which DM is influencing TB-transmission dynamics. 
This, however, will depend on which of the DM-on-TB effects (or combination of effects) is assumed active, as 
each effect may impact TB transmission dynamics differently, with PAFTrue ranging from −5% to 35% (Fig. 5).
Though only two effects had large PAFTrue, most effects had small PAFTrue (Fig. 5). The combined effect, how-
ever, even of small effects, can add up to a substantial impact (Supplementary Fig. S1). If several of the 10 effects 
(large and small) are present and acting simultanously, the impact of DM on TB could be substantially higher 
than expected (Fig. 5 and Supplementary Fig. S2B). This highlights the need to ascertain the exact ES of each 
effect, and suggests that DM could be impacting TB epidemiology to a larger extent than previously thought.
Our study has limitations. We included the plausible TB-DM effects based on a literature review, but we may 
have overlooked effects, particularly if they are not yet supported by evidence. Though there is evidence sup-
porting each considered effect, the evidence is not conclusive for most, and the ES is either imprecise or poorly 
known. We did not include all factors that may influence the incorporated DM-on-TB effects, or the factors that 
may affect directly each of TB or DM burdens individually8,63,73,74. For example, we did not incorporate the impact 
of using anti-DM medications75–77, or HIV as a co-factor63,73,74. However, in India (as in other parts of the world) 
a large proportion of people living with DM are undiagnosed and may have uncontrolled DM8,78–80. Moreover, 
even for those diagnosed with DM, a proportion of them may not be adhering to anti-DM medications81. Despite 
the potential public health implications, prevalence of HIV is relatively low in India at less than 1.0%82, a fact 
that is true for nearly all TB-DM burdened countries outside Africa83, hence, minimally affecting our results and 
conclusions.
We modeled TB’s natural history based on the canonical approach in the literature24,84, but TB has a complex 
natural history that is still far from being settled68,85. We assessed the TB-DM epidemiologic synergy assuming 
endemic and stable levels for TB and DM, with no assessment of the implications of the temporal-dynamics 
and time-varying infectivity profile. The DM-on-TB effects were assumed constant with time, but the fluctu-
ating blood glucose levels in individuals with DM may affect the stability of the rates as assumed in this model. 
The model did not include the varying age-stratification for DM, but DM is strongly age-dependent. Bearing 
these limitations in mind, the aim of the present analysis was to assess the epidemiological implications of the 
TB-DM interactions from a theoretical perspective that focuses on the core interaction effects, and avoids entan-
glement with demographic and temporal effects. Thus, we resorted to a parsimonious model structure where DM 
is included as a fixed proportion of the population and with temporally-invariable DM-on-TB effects, thereby 
presenting an “average” impact of DM on TB rather than a full temporally-varying impact.
We did not explicitly factor multi-drug resistant TB (MDR TB) and the effect of DM on MDR TB in the 
model. However, <5% of newly treated TB cases globally are estimated to have MDR TB86, and thus this is not 
likely to affect our results. We did not factor the effect of intermediate hyperglycemia (pre-DM) on TB, leading to 
plausible underestimation of DM’s impact on TB. We focused on the effects of DM on TB, but the links between 
the two diseases could be bi-directional46, thereby further complicating analyses of their epidemiologic synergy.
In conclusion, we provided a conceptual mapping of how DM affects TB natural history and treatment out-
comes through 10 plausible effects, and investigated the epidemiological impact of each effect on TB-transmission 
dynamics. We used a standardized ES for each effect though in reality each may vary with implications on the HR 
and the PAF. The ESs of these effects are yet to be established with precision, and therefore we cannot determine 
nor draw specific conclusions about the exact and total impact of DM on TB in India. Several effects could not be 
assessed using conventional epidemiologic-study designs of the TB-DM association, and therefore their impact 
may have been overlooked in existing literature. The impact of DM on TB should be assessed using a PAFTrue 
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approach, as the one presented here, since this approach can capture the combined direct and indirect impacts 
of each effect. Thus, the unique contribution of our paper is to highlight the potentially large indirect (true pop-
ulation) effects associated with some pathways, particularly if DM’s effects on TB are dominated by rapid TB 
progression or increased infectiousness.
We found that the indirect impact on TB-transmission dynamics (e.g. onward transmission) of some of the 
effects is large and comparable to the direct impact. Even for effects with small impacts, the combined effect of 
several could be substantial. While the impact of several effects on the HR was limited, the impact on the PAF was 
substantial suggesting that DM could be impacting TB epidemiology to a larger extent than previously thought. 
They also stress the need to assess with precision the ESs of these effects to determine the actual total impact of 
DM on TB. A better understanding of the TB-DM epidemiologic synergy is critical to improved control and pre-
ventive strategies for TB disease burden, and to achieving the goal of TB elimination by 2050.
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